NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the availability of KN95 disposable air filter masks on the Company’s website Avenova.com. The masks are being sold at a price of $59.99 for a package containing 10 masks or $149.99 for a package containing 30 masks. KN95-rated masks are effective at filtering out at least 95% of airborne particles, including microorganisms, dust, pollen and air pollution.

“In light of the shortage of protective masks, we have tapped into our global health supplier network to procure and make available a high-quality, KN95-rated product at the most reasonable price possible,” said Justin Hall, NovaBay CEO. “We received our first shipment of KN95 masks last week, which sold out online very quickly, and expect a second large inventory of masks to be available for shipment today. To meet the immediate need, we had the masks flown in on a rush basis. We have direct access to a large supplier of KN95 masks and encourage organizations ordering quantities of 50,000 or more to contact us directly at 1-800-890-0329 for special pricing.

“We plan to continue providing KN95 masks on Avenova.com for as long as the demand remains,” Mr. Hall added. “In these most unusual of circumstances, it’s gratifying for the NovaBay team to carry out our commitment to marshal all of our talents and resources to benefit the health and wellbeing of people everywhere. We will continue to be here to help accomplish this objective during and after this crisis is over.”

The NK95 disposable masks are constructed with a three-layer filtration system of nonwoven soft and breathable fiber for effective protection. The masks feature extra soft and comfortable elastic ear loops that will not apply pressure to the ears during use and have an adjustable nose bridge strip. The masks come in a single size that fits most faces. They are non-toxic, odorless, non-irritating, contain no dyes and are hypoallergenic and gentle on the skin. The disposable masks should be replaced daily for best hygiene and are ideal for one-time use in a non-medical setting.

The KN95 air filter masks are manufactured by Earntz Nonwoven Co., Ltd. and are CE certified for FFP2 protective mask (EN 149-2001) and meet KN95-level requirements (GB 2626-2006).

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market NEUTROPHASE® for wound care market.

Forward-Looking Statements

This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current re-branding strategy, the launch of a new marketing initiative, and the impact any of these efforts may have on our future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to consumer acceptance of our new branding, and any potential damage to our established goodwill in the marketplace. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay informed on NovaBay’s Progress Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s Website

NovaBay Contact Justin Hall CEO and General Counsel 510-899-8800 jhall@novabay.com

Investor Contact LHA Investor Relations Jody Cain 310-691-7100 jcain@lhai.com

NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more NovaBay Pharmaceuticals Charts.
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more NovaBay Pharmaceuticals Charts.